CR8020

BIOLOGICAL3 trials

Sponsors

Crucell Holland BV, Janssen Pharmaceutical K.K.

Conditions

HealthyInfluenza

Phase 1

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants

WithdrawnNCT02015533

Janssen Pharmaceutical K.K.Healthy

Start: 2013-12-31End: 2014-04-30Updated: 2019-03-25

Phase 2

Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge

CompletedNCT01938352

Crucell Holland BVInfluenza

Start: 2013-10-02End: 2014-01-22Updated: 2019-04-12

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

WithdrawnNCT01992276

Crucell Holland BVInfluenza

Start: 2013-12-31End: 2015-02-28Updated: 2014-03-04